The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tumor response dynamics of advanced non-small-cell lung cancer (NSCLC) patients (pts) treated with commercial PD-1 inhibitors in the clinical setting.
 
Mizuki Nishino
Honoraria - Bayer Yakuhin
Consulting or Advisory Role - Toshiba; WorldCare Clinical, LLC
Research Funding - Merck (Inst)
 
Suzanne Eleanor Dahlberg
Patents, Royalties, Other Intellectual Property - Patent pending for a statistical model assessing tumor growth (Inst)
 
Anika E Adeni
No Relationships to Disclose
 
Christine A. Lydon
No Relationships to Disclose
 
Hiroto Hatabu
Consulting or Advisory Role - Toshiba
Research Funding - Canon USA (Inst); Konica Minolta (Inst); Toshiba (Inst)
 
Pasi A. Janne
Stock and Other Ownership Interests - Gatekeeper Pharmaceuticals
Consulting or Advisory Role - ARIAD; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Merrimack; Pfizer; Roche
Research Funding - Astellas Pharma; AstraZeneca
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a DFCI owned patent on EGFR mutations licensed to Lab Corp. I receive post-marketing royalties from this invention
 
F. Stephen Hodi
Employment - Dana-Farber Cancer Institute
Consulting or Advisory Role - Amgen; EMD Serono; Genentech/Roche; Merck Sharp & Dohme; Novartis
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Other Relationship - Bristol-Myers Squibb; Genentech/Roche
 
Mark M. Awad
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Foundation Medicine; Genentech; Merck; Nektar; Pfizer